Abstract
We present a new preclinical model to study treatment, resolution, and sequelae of severe ascending pyelonephritis. Urinary tract infection (UTI), primarily caused by uropathogenic Escherichia coli (UPEC), is a common disease in children. Severe pyelonephritis is the primary cause of acquired renal scarring in childhood, which may eventually lead to hypertension and chronic kidney disease in a small but important fraction of patients. Preclinical modeling of UTI utilizes almost exclusively females, which (in most mouse strains) exhibit inherent resistance to severe ascending kidney infection; consequently, no existing preclinical model has assessed the consequences of recovery from pyelonephritis following antibiotic treatment. We recently published a novel mini-surgical bladder inoculation technique, with which male C3H/HeN mice develop robust ascending pyelonephritis, highly prevalent renal abscesses, and evidence of fibrosis. Here, we devised and optimized an antibiotic treatment strategy within this male model to more closely reflect the clinical course of pyelonephritis. A 5-day ceftriaxone regimen initiated at the onset of abscess development achieved resolution of bladder and kidney infection. A minority of treated mice displayed persistent histologic abscess at the end of treatment, despite microbiologic cure of pyelonephritis; a matching fraction of mice 1 month later exhibited renal scars featuring fibrosis and ongoing inflammatory infiltrates. Successful antibiotic treatment preserved renal function in almost all infected mice, as assessed by biochemical markers 1 and 5 months post treatment; hydronephrosis was observed as a late effect of treated pyelonephritis. An occasional mouse developed chronic kidney disease, generally reflecting the incidence of this late sequela in humans. In total, this model offers a platform to study the molecular pathogenesis of pyelonephritis, response to antibiotic therapy, and emergence of sequelae including fibrosis and renal scarring. Future studies in this system may inform adjunctive therapies that may reduce the long-term complications of this very common bacterial infection.
- Received April 18, 2017.
- Accepted September 4, 2017.
- © 2017. Published by The Company of Biologists Ltd
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution and reproduction in any medium provided that the original work is properly attributed.
Keywords
Article navigation
Related articles
Cited by...
More in this TOC section
Similar articles
Other journals from The Company of Biologists
Editor’s choice – Diacylglycerol kinase (DGKA) regulates the effect of the epilepsy and bipolar disorder treatment valproic acid in Dictyostelium discoideum
Using a tractable model system, Dictyostelium discoideum, Robin S. B. Williams and colleagues show that diacylglycerol kinase activity might contribute to the cellular mechanism of action of the epilepsy and bipolar disorder treatment, valproic acid. Find out more about the story behind the paper in the first-author interview with Elizabeth Kelly.
Featured article – Independent effects of dietary fat and sucrose content on chondrocyte metabolism and osteoarthritis pathology in mice
The contribution of metabolic factors to obesity-associated knee osteoarthritis is uncertain. Here, Timothy M. Griffin and co-workers show how dietary fat and sucrose independently alter cartilage metabolic enzymes and osteoarthritis pathophysiology in mice.
Featured article – The class I myosin MYO1D binds to lipid and protects against colitis
Using random germline mutagenesis and screening of mice, Bruce Beutler and colleagues determined that loss of MYO1D function in non-hematopoietic tissues renders mice susceptible to colitis induced by dextran sodium sulphate challenge.
First Person interviews
Have you seen our interviews with the early-career first authors of our papers? Recently, we caught up with first authors Wei-Chia Tseng, Elizabeth Kelly, Bum Jun Kim, Lin Song, Jens Tiefenbach, Román Moreno Fernández, Katharina Dannhausen, Eunate Gallardo-Vara, Hongde Li and Yuliya Klymenko & Rebecca Wates.
Journal meeting – Blood disorders: models, mechanisms and therapies
Register your interest in our upcoming meeting on blood disorders and their treatment, organised by DMM Editor-in-Chief Monica Justice, Nancy Speck, Paresh Vyas and Leonard Zon. The meeting will bring together diverse front-line researchers, stimulating discussions across basic research and clinical disciplines, and fostering collaborative links among researchers.
Why should you publish your next paper in DMM?
DMM aims to promote human health by encouraging collaboration between basic and clinical researchers, covering a diverse range of diseases, approaches and models. Our Editors are all active researchers in the field – your peers, colleagues and mentors, who know how much work has gone into every paper. Recently, we have introduced format-free submission, and we accept peer review reports from other journals, making submission as easy as possible for our authors. Send us your next great paper – publish with us and you'll be in good company.
preLights – Human pancreatic islet 3D chromatin architecture provides insights into the genetics of type 2 diabetes
Carmen Adriaens highlights a recent preprint from Jorge Ferrer and colleagues, using a chromatin interactome map of human pancreatic islets to provide a 3D view into type 2 diabetes and pancreatic islet biology. The preLight includes a response from author Inês Cebola, telling more of the background story behind the study.
We are pleased to announce that recent preLights selected for the translational biology community will feature regularly as part of our issue Table of Contents.